Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2008 1
2009 2
2013 2
2015 4
2016 6
2017 20
2018 21
2019 34
2020 28
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 32188652

102 results
Results by year
Filters applied: . Clear all
Page 1
Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma.
Agarwal K, Yousaf N, Morganstein D. Agarwal K, et al. Clin Med (Lond). 2020 Mar;20(2):163-168. doi: 10.7861/clinmed.2018-0440. Clin Med (Lond). 2020. PMID: 32188652 Free PMC article.
Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors.
Williams KJ, Grauer DW, Henry DW, Rockey ML. Williams KJ, et al. J Oncol Pharm Pract. 2019 Apr;25(3):544-550. doi: 10.1177/1078155217744872. Epub 2017 Dec 9. J Oncol Pharm Pract. 2019. PMID: 29224458
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.
Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, Cohen J, Sullivan RJ. Faje AT, et al. Cancer. 2018 Sep 15;124(18):3706-3714. doi: 10.1002/cncr.31629. Epub 2018 Jul 5. Cancer. 2018. PMID: 29975414 Free article.
Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report.
Ngo L, Miller E, Valen P, Gertner E. Ngo L, et al. J Med Case Rep. 2018 Feb 26;12(1):48. doi: 10.1186/s13256-018-1579-1. J Med Case Rep. 2018. PMID: 29478412 Free PMC article.
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, Thompson MA, Puzanov I, Greer JP, Rapisuwon S, Postow M, Davies MA, Eroglu Z, Johnson D. Shiuan E, et al. J Immunother Cancer. 2017 Feb 21;5:8. doi: 10.1186/s40425-017-0210-0. eCollection 2017. J Immunother Cancer. 2017. PMID: 28239462 Free PMC article.
Glucocorticoids and immune checkpoint inhibitors in glioblastoma.
Kelly WJ, Gilbert MR. Kelly WJ, et al. J Neurooncol. 2020 Feb 27. doi: 10.1007/s11060-020-03439-2. Online ahead of print. J Neurooncol. 2020. PMID: 32108294 Review.
Systemic treatments for metastatic cutaneous melanoma.
Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Pasquali S, et al. Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article. Review.
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL. Tetzlaff MT, et al. J Immunother Cancer. 2018 Feb 12;6(1):14. doi: 10.1186/s40425-018-0323-0. J Immunother Cancer. 2018. PMID: 29433571 Free PMC article.
THYROID DYSFUNCTION, RECOVERY, AND PROGNOSIS IN MELANOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A RETROSPECTIVE REVIEW.
Al Mushref M, Guido PA, Collichio FA, Moore DT, Clemmons DR. Al Mushref M, et al. Endocr Pract. 2020 Jan;26(1):36-42. doi: 10.4158/EP-2019-0244. Epub 2019 Aug 28. Endocr Pract. 2020. PMID: 31461358
Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.
Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F, Krebs M, Carter L, Thistlethwaite F, Graham D, Cook N. Tinsley N, et al. Oncologist. 2020 Jan;25(1):55-63. doi: 10.1634/theoncologist.2019-0160. Epub 2019 Jul 10. Oncologist. 2020. PMID: 31292268 Free PMC article.
102 results
Jump to page
Feedback